Loading company analysis...
Sector coverage
28 full analyses · 71.7/100 average rating. Rankings are research opinions, not recommendations.
Eli Lilly is delivering exceptional growth through Mounjaro and Zepbound while expanding its cardiometabolic pipeline and manufacturing capacity.
Vertex Pharmaceuticals dominates the cystic fibrosis treatment market and is expanding into new therapeutic areas including pain management and diabetes.
Intuitive Surgical is the dominant player in robotic assisted surgery through its da Vinci system, benefiting from a highly recurring instrument and service revenue model.
Boston Scientific makes medical devices across cardiovascular, endoscopy, and urology categories, benefiting from consistent new product innovation driving above average growth.
Stryker Corporation makes orthopedic implants, surgical equipment, and medical technology products, benefiting from steady demand tied to an aging population.
Idexx Laboratories is a leading provider of veterinary diagnostic products and services, benefiting from growing pet ownership and increased spending on companion animal healthcare.
Edwards Lifesciences is a leading maker of heart valve replacement technology, benefiting from continued adoption of minimally invasive structural heart procedures.
Abbott Laboratories operates a diversified healthcare business spanning medical devices, diagnostics, nutrition, and branded generic pharmaceuticals.
Danaher operates a portfolio of life sciences and diagnostics businesses, using its disciplined operating system to drive consistent margin improvement across acquisitions.
HCA Healthcare is the largest for-profit hospital operator in the US, benefiting from scale efficiencies and steady demand for healthcare services.
Thermo Fisher Scientific supplies lab equipment, reagents, and services used broadly across pharmaceutical, biotech, academic, and industrial research.
McKesson Corporation is one of the largest pharmaceutical distributors in the US, operating a high volume, low margin business with steady, predictable cash flow.
Amgen is a large biotech with a diversified portfolio spanning inflammation, oncology, and bone health, along with a growing obesity drug candidate.
Cencora is one of the largest pharmaceutical distributors globally, operating a high volume, low margin business with steady, predictable cash flow similar to other major distributors.
Gilead Sciences is a leading HIV treatment company expanding into oncology and other therapeutic areas to diversify beyond its core franchise.
Cardinal Health is one of the largest pharmaceutical and medical product distributors in the US, operating a high volume, low margin business with steady, predictable cash flow.
Merck leans heavily on its oncology franchise Keytruda while building out newer vaccine and animal health businesses ahead of patent expiration.
Regeneron Pharmaceuticals is a biotechnology company known for its eye disease treatment Eylea, working to diversify its pipeline as biosimilar competition emerges.
Medtronic is a large, diversified medical device company spanning cardiac, diabetes, surgical, and neuroscience products, working to reaccelerate growth after a period of slower innovation.
Cigna is a diversified health services company combining health insurance with a large pharmacy benefit management business through Evernorth.
Becton Dickinson makes medical devices and diagnostic products across a broad portfolio, working through a planned separation of its biosciences and diagnostics business.
Elevance Health is one of the largest health insurers in the US, operating Blue Cross Blue Shield plans across multiple states alongside a growing healthcare services business.
Pfizer is working to rebuild its growth pipeline following the decline of pandemic era vaccine and treatment revenue, with a large and diversified drug portfolio.
CVS Health combines pharmacy retail, pharmacy benefit management, and health insurance under one company, though its insurance segment has faced recent profitability pressure.
Bristol Myers Squibb is working through legacy product patent expirations while building out its newer oncology, immunology, and neuroscience pipeline.
AbbVie has successfully shifted growth toward Skyrizi, Rinvoq, and neuroscience, while acquisitions, high debt, and product concentration remain central risks.
Johnson & Johnson combines a diversified medicine pipeline and global MedTech portfolio with dependable cash flow, while patent erosion and litigation remain important risks.
UnitedHealth is showing a meaningful earnings and medical-cost recovery across UnitedHealthcare and Optum, but membership contraction, regulation, and investigations remain central risks.
